药学与临床研究
藥學與臨床研究
약학여림상연구
PHARMACEUTICAL AND CLINICAL RESEARCH
2015年
3期
263-266
,共4页
张烨%肖青青%申璐%杨劲
張燁%肖青青%申璐%楊勁
장엽%초청청%신로%양경
帕拉德福韦%LC-MS/MS%药代动力学
帕拉德福韋%LC-MS/MS%藥代動力學
파랍덕복위%LC-MS/MS%약대동역학
Pradefovir%LC-MS/MS%Pharmacokinetics
目的:建立人血清帕拉德福韦浓度检测方法并运用于人体药代动力学研究。方法:血清样品乙腈沉淀蛋白处理后,采用液相色谱串联质谱(LC-MS/MS)法测定。以0.2 mmol·L-1乙酸铵水溶液(A)-乙腈(B)为流动相,Thermo BDS HYPERSIL C18 column(150 mm×2.1 mm,5μm)分离,梯度洗脱。帕拉德福韦及内标(恩替卡韦)监测离子对为m/z 424.1→151.0;m/z 278.3→152.1。运用建立的方法测定健康受试者血清中药物浓度。结果:帕拉德福韦血清药物浓度在0.5~500 ng·mL-1的范围内线性关系良好,方法回收率、日内及日间精密度均符合方法学要求。结论:该方法专属性强、灵敏度高,可用于帕拉德福韦人体药动学研究。
目的:建立人血清帕拉德福韋濃度檢測方法併運用于人體藥代動力學研究。方法:血清樣品乙腈沉澱蛋白處理後,採用液相色譜串聯質譜(LC-MS/MS)法測定。以0.2 mmol·L-1乙痠銨水溶液(A)-乙腈(B)為流動相,Thermo BDS HYPERSIL C18 column(150 mm×2.1 mm,5μm)分離,梯度洗脫。帕拉德福韋及內標(恩替卡韋)鑑測離子對為m/z 424.1→151.0;m/z 278.3→152.1。運用建立的方法測定健康受試者血清中藥物濃度。結果:帕拉德福韋血清藥物濃度在0.5~500 ng·mL-1的範圍內線性關繫良好,方法迴收率、日內及日間精密度均符閤方法學要求。結論:該方法專屬性彊、靈敏度高,可用于帕拉德福韋人體藥動學研究。
목적:건립인혈청파랍덕복위농도검측방법병운용우인체약대동역학연구。방법:혈청양품을정침정단백처리후,채용액상색보천련질보(LC-MS/MS)법측정。이0.2 mmol·L-1을산안수용액(A)-을정(B)위류동상,Thermo BDS HYPERSIL C18 column(150 mm×2.1 mm,5μm)분리,제도세탈。파랍덕복위급내표(은체잡위)감측리자대위m/z 424.1→151.0;m/z 278.3→152.1。운용건립적방법측정건강수시자혈청중약물농도。결과:파랍덕복위혈청약물농도재0.5~500 ng·mL-1적범위내선성관계량호,방법회수솔、일내급일간정밀도균부합방법학요구。결론:해방법전속성강、령민도고,가용우파랍덕복위인체약동학연구。
Objective: To set up a liquid chromatographic-tandem mass spectrometric (LC/MS/MS) method for the determination of pradefovir in human serum and to apply it to the clinical pharmacokinet-ics. Methods: The serum sample was precipitated by acetonitrile, and the supernatant was analyzed by LC-MS/MS. Chromatographic separation was performed on a Thermo BDS HYPERSIL C18 column (150 mm× 2.1 mm, 5μm) with a gradient elution system of 0.2 mmol·L-1 ammonium acetate buffer - acetonitrile at a flow-rate of 0.3 mL·min-1. The ion transitions recorded in multiple reaction monitoring mode were m/z 424.1([M+H]+) →151.0 for pradefovir and m/z 278.3([M+H]+) →152.1 for the internal standard. The estab-lished method was used to determine the serum concentration of pradefovir in healthy subjects. Results:The linear range of calibration curves for pradefovir was 0.5-500 ng·mL-1. The recovery and the intra-and inter-assay precisions met the requirements of bioanalytical methods. Conclusions: The method is proven to be rapid, specific and sensitive. It can be used for the clinical pharmacokinetic study.